Novartis AG, the Swiss pharmaceutical major and promoter of Novartis India Limited, has filed a mandatory regulatory disclosure with BSE Limited confirming that no lien has been created on its equity holdings and reiterating details of its previously announced divestment agreement.

Lien Declaration on Equity Holdings

In compliance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Novartis AG declared that it has not created any lien on its 1.74 crore equity shares in Novartis India Limited, either directly or indirectly, as of March 31, 2026.

Sale Agreement Confirmation

The disclosure reaffirmed the sale and purchase agreement (SPA) entered into on February 19, 2026, for the complete divestment of Novartis AG's stake in its Indian subsidiary. The transaction involves three strategic acquirers who will collectively acquire the entire promoter holding.

Acquirer Details

The sale agreement encompasses three distinct entities:

• WaveRise Investments Limited (Acquirer 1)
• ChrysCapital Fund X (Acquirer 2)
• Two Infinity Partners (Acquirer 3)

Regulatory Compliance

The filing demonstrates Novartis AG's adherence to Indian securities regulations governing substantial shareholding transactions. The disclosure was addressed to BSE Limited and copied to the Audit Committee of Novartis India Limited, ensuring comprehensive regulatory notification.

The document was signed by authorized signatories Lukas Förtsch and Stefan Thommen, representing Novartis AG's commitment to maintaining transparency throughout the divestment process. This regulatory filing provides stakeholders with updated information on the transaction's progress and confirms the integrity of the shareholding structure pending completion of the sale.

Novartis India Limited has officially announced a Board of Directors meeting scheduled for May 12, 2026, to review and approve the company's audited financial results for the fourth quarter and full financial year ended March 31, 2026. The announcement was made through a formal communication to BSE Limited on March 31, 2026, in compliance with regulatory requirements.

Board Meeting Details

The pharmaceutical company has scheduled the board meeting in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will focus on considering and approving the audited financial results for Q4FY26.

Trading Window Closure

In connection with the upcoming board meeting, Novartis India Limited has announced the closure of its trading window for designated persons, insiders, connected persons, and their immediate relatives. This measure ensures compliance with insider trading regulations and maintains market integrity.

Corporate Governance and Compliance

The trading window closure is implemented pursuant to the company's 'Code of Conduct to regulate, monitor and report share trading by Designated Persons/Insiders/Connected Persons and their immediate relatives.' This code operates in conjunction with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended.

The communication was digitally signed by Chandni Maru, Company Secretary and Compliance Officer, emphasizing the company's commitment to maintaining transparency and regulatory compliance in its corporate governance practices. The company is headquartered at Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra East, Mumbai.